| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Stroke | 99 | 2023 | 609 | 17.620 |
Why?
|
| Ischemic Attack, Transient | 17 | 2022 | 48 | 4.280 |
Why?
|
| Brain Ischemia | 23 | 2018 | 147 | 4.160 |
Why?
|
| Pregnancy Complications, Cardiovascular | 11 | 2020 | 25 | 2.670 |
Why?
|
| Women's Health | 13 | 2014 | 235 | 2.640 |
Why?
|
| Sex Characteristics | 11 | 2022 | 172 | 2.030 |
Why?
|
| Secondary Prevention | 12 | 2020 | 65 | 1.910 |
Why?
|
| Humans | 133 | 2023 | 32799 | 1.780 |
Why?
|
| Female | 97 | 2022 | 20262 | 1.720 |
Why?
|
| Migraine Disorders | 6 | 2014 | 69 | 1.680 |
Why?
|
| Patient Readmission | 5 | 2021 | 134 | 1.550 |
Why?
|
| Risk Factors | 44 | 2022 | 3974 | 1.430 |
Why?
|
| Estrogen Replacement Therapy | 8 | 2014 | 195 | 1.390 |
Why?
|
| Patient Discharge | 15 | 2022 | 204 | 1.290 |
Why?
|
| Pregnancy | 22 | 2020 | 981 | 1.270 |
Why?
|
| Pregnancy Complications | 6 | 2017 | 111 | 1.260 |
Why?
|
| Subacute Care | 6 | 2022 | 15 | 1.170 |
Why?
|
| Medicare | 5 | 2022 | 213 | 1.100 |
Why?
|
| Menopause | 5 | 2021 | 97 | 1.080 |
Why?
|
| Telemedicine | 3 | 2023 | 117 | 1.060 |
Why?
|
| Aged | 49 | 2022 | 10538 | 1.030 |
Why?
|
| Hypertension | 7 | 2020 | 976 | 0.980 |
Why?
|
| United States | 30 | 2022 | 4109 | 0.910 |
Why?
|
| Male | 53 | 2023 | 19642 | 0.880 |
Why?
|
| Pre-Eclampsia | 2 | 2018 | 66 | 0.810 |
Why?
|
| Patient-Centered Care | 3 | 2018 | 72 | 0.780 |
Why?
|
| Middle Aged | 45 | 2020 | 12126 | 0.770 |
Why?
|
| Anticoagulants | 7 | 2018 | 136 | 0.730 |
Why?
|
| Fee-for-Service Plans | 1 | 2021 | 12 | 0.720 |
Why?
|
| Hormone Replacement Therapy | 3 | 2020 | 89 | 0.700 |
Why?
|
| Hospitals | 7 | 2019 | 109 | 0.680 |
Why?
|
| Hypertension, Pregnancy-Induced | 2 | 2018 | 13 | 0.680 |
Why?
|
| Postpartum Period | 3 | 2018 | 37 | 0.670 |
Why?
|
| Sinus Thrombosis, Intracranial | 1 | 2020 | 4 | 0.650 |
Why?
|
| Venous Thrombosis | 3 | 2018 | 48 | 0.630 |
Why?
|
| Primary Prevention | 3 | 2014 | 56 | 0.620 |
Why?
|
| Hydroxymethylglutaryl-CoA Reductase Inhibitors | 5 | 2017 | 146 | 0.610 |
Why?
|
| Vasospasm, Intracranial | 1 | 2019 | 13 | 0.610 |
Why?
|
| Vasoconstriction | 1 | 2019 | 43 | 0.610 |
Why?
|
| Cardiovascular Diseases | 8 | 2021 | 1140 | 0.600 |
Why?
|
| Cerebrovascular Disorders | 1 | 2019 | 50 | 0.590 |
Why?
|
| Cerebral Hemorrhage | 5 | 2020 | 70 | 0.580 |
Why?
|
| Intracranial Thrombosis | 3 | 2014 | 8 | 0.570 |
Why?
|
| Neurology | 5 | 2020 | 48 | 0.540 |
Why?
|
| Brain Diseases | 1 | 2018 | 38 | 0.540 |
Why?
|
| Aged, 80 and over | 19 | 2020 | 4032 | 0.530 |
Why?
|
| Research Design | 6 | 2021 | 331 | 0.530 |
Why?
|
| Thrombolytic Therapy | 1 | 2017 | 64 | 0.530 |
Why?
|
| Practice Guidelines as Topic | 5 | 2019 | 412 | 0.520 |
Why?
|
| Vascular Diseases | 2 | 2009 | 68 | 0.520 |
Why?
|
| Severity of Illness Index | 5 | 2020 | 881 | 0.500 |
Why?
|
| Nurse Practitioners | 1 | 2016 | 11 | 0.490 |
Why?
|
| Mobility Limitation | 1 | 2017 | 220 | 0.480 |
Why?
|
| Depression | 4 | 2017 | 448 | 0.480 |
Why?
|
| Patient Education as Topic | 5 | 2018 | 265 | 0.470 |
Why?
|
| American Heart Association | 7 | 2014 | 87 | 0.460 |
Why?
|
| Upper Extremity | 1 | 2015 | 59 | 0.450 |
Why?
|
| Antineoplastic Agents, Hormonal | 2 | 2005 | 43 | 0.450 |
Why?
|
| Tamoxifen | 2 | 2005 | 59 | 0.440 |
Why?
|
| Lower Extremity | 1 | 2015 | 107 | 0.440 |
Why?
|
| Antidepressive Agents | 2 | 2012 | 74 | 0.440 |
Why?
|
| Societies, Medical | 2 | 2019 | 163 | 0.430 |
Why?
|
| Guidelines as Topic | 1 | 2014 | 49 | 0.410 |
Why?
|
| Registries | 7 | 2017 | 315 | 0.410 |
Why?
|
| Aspirin | 6 | 2018 | 62 | 0.400 |
Why?
|
| Atrial Fibrillation | 5 | 2017 | 391 | 0.380 |
Why?
|
| Hospitals, Community | 1 | 2012 | 12 | 0.380 |
Why?
|
| Treatment Outcome | 14 | 2021 | 3438 | 0.370 |
Why?
|
| Quality Assurance, Health Care | 1 | 2012 | 72 | 0.360 |
Why?
|
| Homocysteine | 2 | 2020 | 15 | 0.360 |
Why?
|
| Hyperlipidemias | 3 | 2014 | 56 | 0.360 |
Why?
|
| Incidence | 10 | 2018 | 1239 | 0.360 |
Why?
|
| Continuity of Patient Care | 1 | 2012 | 72 | 0.360 |
Why?
|
| Quality of Life | 3 | 2017 | 961 | 0.350 |
Why?
|
| Antihypertensive Agents | 4 | 2018 | 352 | 0.340 |
Why?
|
| Depressive Disorder | 1 | 2011 | 77 | 0.340 |
Why?
|
| Cerebral Arteries | 2 | 2014 | 19 | 0.340 |
Why?
|
| Platelet Aggregation Inhibitors | 5 | 2017 | 85 | 0.340 |
Why?
|
| Pulsatile Flow | 3 | 2015 | 24 | 0.340 |
Why?
|
| Premenstrual Syndrome | 1 | 2010 | 3 | 0.340 |
Why?
|
| Prevalence | 6 | 2021 | 1002 | 0.330 |
Why?
|
| Risk | 2 | 2008 | 315 | 0.320 |
Why?
|
| Aftercare | 4 | 2022 | 34 | 0.320 |
Why?
|
| Models, Statistical | 1 | 2011 | 180 | 0.310 |
Why?
|
| Time Factors | 12 | 2018 | 2183 | 0.310 |
Why?
|
| Prognosis | 7 | 2018 | 1544 | 0.300 |
Why?
|
| North Carolina | 8 | 2021 | 1546 | 0.300 |
Why?
|
| Life Change Events | 1 | 2009 | 20 | 0.300 |
Why?
|
| Appointments and Schedules | 1 | 2009 | 22 | 0.300 |
Why?
|
| Puerperal Disorders | 3 | 2017 | 5 | 0.300 |
Why?
|
| Randomized Controlled Trials as Topic | 4 | 2011 | 532 | 0.300 |
Why?
|
| Adult | 16 | 2018 | 9561 | 0.280 |
Why?
|
| Headache Disorders, Primary | 1 | 2008 | 3 | 0.280 |
Why?
|
| Risk Assessment | 12 | 2020 | 1460 | 0.280 |
Why?
|
| Longitudinal Studies | 9 | 2017 | 779 | 0.280 |
Why?
|
| Clinical Trials as Topic | 4 | 2020 | 307 | 0.270 |
Why?
|
| Case-Control Studies | 5 | 2014 | 876 | 0.270 |
Why?
|
| Hospitalization | 5 | 2017 | 488 | 0.270 |
Why?
|
| Thrombectomy | 2 | 2018 | 75 | 0.270 |
Why?
|
| Recovery of Function | 5 | 2020 | 203 | 0.270 |
Why?
|
| Healthcare Disparities | 4 | 2017 | 178 | 0.270 |
Why?
|
| Follow-Up Studies | 7 | 2018 | 2284 | 0.260 |
Why?
|
| Medication Adherence | 4 | 2018 | 160 | 0.250 |
Why?
|
| Program Evaluation | 2 | 2020 | 181 | 0.250 |
Why?
|
| Quality of Health Care | 2 | 2020 | 147 | 0.250 |
Why?
|
| Retrospective Studies | 7 | 2020 | 3701 | 0.240 |
Why?
|
| Exercise | 2 | 2022 | 679 | 0.240 |
Why?
|
| Somatoform Disorders | 1 | 2005 | 7 | 0.240 |
Why?
|
| Magnetic Resonance Imaging | 6 | 2019 | 1307 | 0.240 |
Why?
|
| Disability Evaluation | 4 | 2017 | 238 | 0.240 |
Why?
|
| Intracranial Hemorrhages | 2 | 2017 | 33 | 0.240 |
Why?
|
| Electroencephalography | 1 | 2005 | 72 | 0.230 |
Why?
|
| Intracranial Arteriosclerosis | 1 | 2005 | 12 | 0.230 |
Why?
|
| African Americans | 3 | 2020 | 1424 | 0.230 |
Why?
|
| Seizures | 1 | 2005 | 64 | 0.230 |
Why?
|
| Survivors | 3 | 2023 | 168 | 0.230 |
Why?
|
| Internship and Residency | 1 | 2009 | 324 | 0.230 |
Why?
|
| Tetrazoles | 2 | 2015 | 63 | 0.220 |
Why?
|
| Estrogens | 1 | 2005 | 169 | 0.220 |
Why?
|
| Selective Estrogen Receptor Modulators | 1 | 2004 | 35 | 0.220 |
Why?
|
| Economics, Pharmaceutical | 1 | 2004 | 5 | 0.210 |
Why?
|
| Prospective Studies | 8 | 2017 | 2327 | 0.210 |
Why?
|
| Age Factors | 6 | 2012 | 1197 | 0.210 |
Why?
|
| Anticholesteremic Agents | 1 | 2004 | 38 | 0.210 |
Why?
|
| Thrombophilia | 1 | 2003 | 8 | 0.200 |
Why?
|
| Contraceptives, Oral, Hormonal | 2 | 2018 | 8 | 0.200 |
Why?
|
| Odds Ratio | 6 | 2017 | 467 | 0.200 |
Why?
|
| Patient Selection | 3 | 2018 | 281 | 0.200 |
Why?
|
| Emergency Medical Services | 2 | 2019 | 181 | 0.200 |
Why?
|
| Hemianopsia | 1 | 2023 | 6 | 0.200 |
Why?
|
| Comorbidity | 4 | 2014 | 573 | 0.190 |
Why?
|
| Vascular Cell Adhesion Molecule-1 | 2 | 2020 | 17 | 0.190 |
Why?
|
| Sex Factors | 3 | 2020 | 675 | 0.190 |
Why?
|
| Blood Coagulation Tests | 1 | 2002 | 8 | 0.190 |
Why?
|
| Blood Coagulation Disorders | 1 | 2002 | 13 | 0.190 |
Why?
|
| Caregivers | 3 | 2018 | 121 | 0.180 |
Why?
|
| Ambulatory Care | 1 | 2022 | 109 | 0.180 |
Why?
|
| Skilled Nursing Facilities | 2 | 2021 | 12 | 0.180 |
Why?
|
| Predictive Value of Tests | 5 | 2017 | 887 | 0.180 |
Why?
|
| Breast Neoplasms | 2 | 2005 | 754 | 0.180 |
Why?
|
| Estrogens, Conjugated (USP) | 2 | 2014 | 138 | 0.170 |
Why?
|
| Endpoint Determination | 1 | 2021 | 20 | 0.170 |
Why?
|
| Fibrinolytic Agents | 2 | 2011 | 69 | 0.170 |
Why?
|
| Mass Screening | 1 | 2003 | 268 | 0.170 |
Why?
|
| Hyperhomocysteinemia | 1 | 2020 | 5 | 0.170 |
Why?
|
| Activities of Daily Living | 2 | 2014 | 258 | 0.170 |
Why?
|
| Disabled Persons | 2 | 2014 | 105 | 0.170 |
Why?
|
| Gene Expression Regulation | 2 | 2014 | 475 | 0.170 |
Why?
|
| Gene Expression | 2 | 2012 | 334 | 0.170 |
Why?
|
| Ultrasonography, Doppler, Transcranial | 3 | 2015 | 31 | 0.160 |
Why?
|
| Gene Expression Profiling | 5 | 2014 | 316 | 0.160 |
Why?
|
| Health Care Costs | 1 | 2021 | 122 | 0.160 |
Why?
|
| Memory Disorders | 1 | 2020 | 54 | 0.160 |
Why?
|
| Health Services Needs and Demand | 1 | 2020 | 80 | 0.150 |
Why?
|
| Linear Models | 3 | 2017 | 445 | 0.150 |
Why?
|
| Organizational Policy | 1 | 2019 | 24 | 0.150 |
Why?
|
| Clinical Competence | 1 | 2002 | 338 | 0.150 |
Why?
|
| Certification | 1 | 2019 | 28 | 0.150 |
Why?
|
| Health Status Indicators | 2 | 2009 | 74 | 0.150 |
Why?
|
| Pilot Projects | 2 | 2012 | 565 | 0.150 |
Why?
|
| Prenatal Care | 2 | 2017 | 54 | 0.150 |
Why?
|
| Data Mining | 1 | 2018 | 13 | 0.140 |
Why?
|
| Coronavirus Infections | 1 | 2020 | 98 | 0.140 |
Why?
|
| Pneumonia, Viral | 1 | 2020 | 102 | 0.140 |
Why?
|
| Drug Therapy, Combination | 3 | 2014 | 289 | 0.140 |
Why?
|
| Memory | 1 | 2020 | 191 | 0.140 |
Why?
|
| Delivery of Health Care | 1 | 2020 | 166 | 0.140 |
Why?
|
| Health Promotion | 1 | 2020 | 255 | 0.140 |
Why?
|
| Health Policy | 1 | 2019 | 93 | 0.140 |
Why?
|
| Tissue Plasminogen Activator | 1 | 2018 | 41 | 0.140 |
Why?
|
| Ethics, Research | 1 | 2018 | 23 | 0.140 |
Why?
|
| Syndrome | 1 | 2018 | 74 | 0.140 |
Why?
|
| Informed Consent | 1 | 2018 | 40 | 0.140 |
Why?
|
| Delivery, Obstetric | 1 | 2018 | 58 | 0.140 |
Why?
|
| Endarterectomy, Carotid | 1 | 2017 | 30 | 0.140 |
Why?
|
| Professional Practice | 1 | 2017 | 24 | 0.140 |
Why?
|
| Delivery of Health Care, Integrated | 1 | 2018 | 34 | 0.140 |
Why?
|
| Public Health Practice | 1 | 2017 | 8 | 0.130 |
Why?
|
| Cardiomyopathies | 1 | 2018 | 66 | 0.130 |
Why?
|
| Sex Distribution | 2 | 2014 | 185 | 0.130 |
Why?
|
| Women's Rights | 1 | 2017 | 4 | 0.130 |
Why?
|
| Chronic Disease | 2 | 2015 | 410 | 0.130 |
Why?
|
| Cohort Studies | 3 | 2011 | 1844 | 0.130 |
Why?
|
| Myocardial Ischemia | 1 | 2017 | 105 | 0.130 |
Why?
|
| Electronic Health Records | 1 | 2018 | 182 | 0.130 |
Why?
|
| Quality Indicators, Health Care | 1 | 2017 | 60 | 0.130 |
Why?
|
| Brain | 4 | 2023 | 946 | 0.120 |
Why?
|
| Evidence-Based Medicine | 3 | 2014 | 215 | 0.120 |
Why?
|
| Health Status | 3 | 2018 | 402 | 0.120 |
Why?
|
| Diagnosis, Differential | 2 | 2009 | 526 | 0.120 |
Why?
|
| Blood Pressure | 3 | 2014 | 862 | 0.120 |
Why?
|
| Expert Testimony | 1 | 2015 | 11 | 0.120 |
Why?
|
| HIV Infections | 1 | 2021 | 424 | 0.120 |
Why?
|
| Cognition | 2 | 2020 | 551 | 0.120 |
Why?
|
| Uric Acid | 1 | 2015 | 27 | 0.120 |
Why?
|
| Home Care Services | 1 | 2016 | 53 | 0.120 |
Why?
|
| Educational Status | 2 | 2014 | 183 | 0.120 |
Why?
|
| Histoplasmosis | 1 | 2015 | 2 | 0.120 |
Why?
|
| Adolescent | 6 | 2012 | 3638 | 0.110 |
Why?
|
| Vasculitis | 1 | 2015 | 24 | 0.110 |
Why?
|
| Algorithms | 1 | 2018 | 511 | 0.110 |
Why?
|
| Coronary Disease | 2 | 2008 | 214 | 0.110 |
Why?
|
| Basilar Artery | 1 | 2014 | 9 | 0.110 |
Why?
|
| Middle Cerebral Artery | 1 | 2014 | 13 | 0.110 |
Why?
|
| Cost-Benefit Analysis | 3 | 2021 | 194 | 0.110 |
Why?
|
| Leukoencephalopathies | 1 | 2014 | 12 | 0.110 |
Why?
|
| Health Services for the Aged | 1 | 2014 | 25 | 0.110 |
Why?
|
| Causality | 1 | 2014 | 39 | 0.110 |
Why?
|
| Life Style | 2 | 2014 | 407 | 0.110 |
Why?
|
| Biomedical Research | 2 | 2020 | 171 | 0.110 |
Why?
|
| Intracranial Embolism | 1 | 2014 | 14 | 0.110 |
Why?
|
| Tomography, X-Ray Computed | 1 | 2019 | 947 | 0.110 |
Why?
|
| Leukocytes | 1 | 2014 | 57 | 0.110 |
Why?
|
| Risk Adjustment | 1 | 2014 | 26 | 0.100 |
Why?
|
| Proportional Hazards Models | 3 | 2017 | 764 | 0.100 |
Why?
|
| Risk Reduction Behavior | 1 | 2014 | 125 | 0.100 |
Why?
|
| Hypercholesterolemia | 1 | 2014 | 73 | 0.100 |
Why?
|
| Employment | 1 | 2014 | 51 | 0.100 |
Why?
|
| Income | 1 | 2014 | 67 | 0.100 |
Why?
|
| Image Interpretation, Computer-Assisted | 1 | 2014 | 112 | 0.100 |
Why?
|
| Ischemia | 1 | 2014 | 104 | 0.100 |
Why?
|
| Young Adult | 2 | 2017 | 2730 | 0.100 |
Why?
|
| Reperfusion | 1 | 2012 | 21 | 0.090 |
Why?
|
| African Continental Ancestry Group | 1 | 2013 | 363 | 0.090 |
Why?
|
| Chromosomes, Human, Y | 1 | 2012 | 2 | 0.090 |
Why?
|
| Guideline Adherence | 3 | 2020 | 120 | 0.090 |
Why?
|
| Chromosomes, Human, X | 1 | 2011 | 12 | 0.090 |
Why?
|
| Feasibility Studies | 1 | 2012 | 308 | 0.090 |
Why?
|
| Aging | 3 | 2021 | 938 | 0.090 |
Why?
|
| Oligonucleotide Array Sequence Analysis | 4 | 2012 | 154 | 0.090 |
Why?
|
| Logistic Models | 3 | 2017 | 783 | 0.090 |
Why?
|
| Cognition Disorders | 2 | 2015 | 370 | 0.090 |
Why?
|
| Tryptamines | 1 | 2010 | 3 | 0.080 |
Why?
|
| Naproxen | 1 | 2010 | 7 | 0.080 |
Why?
|
| National Institutes of Health (U.S.) | 1 | 2010 | 29 | 0.080 |
Why?
|
| Obsessive Behavior | 1 | 2010 | 3 | 0.080 |
Why?
|
| Menstrual Cycle | 1 | 2010 | 27 | 0.080 |
Why?
|
| Nervous System Diseases | 1 | 2010 | 41 | 0.080 |
Why?
|
| Factor Analysis, Statistical | 1 | 2010 | 76 | 0.080 |
Why?
|
| Fetus | 1 | 2010 | 86 | 0.080 |
Why?
|
| Physical Therapy Modalities | 1 | 2010 | 67 | 0.080 |
Why?
|
| Urban Population | 1 | 2011 | 93 | 0.080 |
Why?
|
| Academic Medical Centers | 2 | 2020 | 162 | 0.080 |
Why?
|
| Neuropsychological Tests | 3 | 2020 | 363 | 0.080 |
Why?
|
| Primary Health Care | 1 | 2012 | 231 | 0.080 |
Why?
|
| Behavior Therapy | 1 | 2010 | 103 | 0.080 |
Why?
|
| Analgesics | 1 | 2010 | 109 | 0.080 |
Why?
|
| Health Personnel | 1 | 2010 | 130 | 0.080 |
Why?
|
| Mental Disorders | 1 | 2010 | 125 | 0.080 |
Why?
|
| European Continental Ancestry Group | 1 | 2013 | 1163 | 0.080 |
Why?
|
| Confidence Intervals | 1 | 2009 | 148 | 0.080 |
Why?
|
| Medroxyprogesterone Acetate | 1 | 2009 | 100 | 0.080 |
Why?
|
| Telephone | 2 | 2019 | 58 | 0.070 |
Why?
|
| Psychometrics | 1 | 2009 | 137 | 0.070 |
Why?
|
| Multicenter Studies as Topic | 1 | 2009 | 111 | 0.070 |
Why?
|
| Contraceptives, Oral | 1 | 2008 | 22 | 0.070 |
Why?
|
| Rural Population | 1 | 2011 | 286 | 0.070 |
Why?
|
| Teaching | 1 | 2009 | 61 | 0.070 |
Why?
|
| Regression Analysis | 1 | 2009 | 288 | 0.070 |
Why?
|
| Frail Elderly | 1 | 2009 | 71 | 0.070 |
Why?
|
| Canada | 2 | 2017 | 64 | 0.070 |
Why?
|
| Pregnancy Outcome | 1 | 2008 | 91 | 0.070 |
Why?
|
| Patient Compliance | 1 | 2009 | 218 | 0.070 |
Why?
|
| Endometriosis | 1 | 2007 | 25 | 0.060 |
Why?
|
| Dementia | 1 | 2009 | 245 | 0.060 |
Why?
|
| Diabetes Complications | 1 | 2008 | 182 | 0.060 |
Why?
|
| Postmenopause | 2 | 2009 | 427 | 0.060 |
Why?
|
| Analysis of Variance | 2 | 2009 | 459 | 0.060 |
Why?
|
| Platelet Glycoprotein GPIIb-IIIa Complex | 1 | 2006 | 30 | 0.060 |
Why?
|
| Videotape Recording | 1 | 2005 | 13 | 0.060 |
Why?
|
| Carotid Arteries | 1 | 2005 | 101 | 0.060 |
Why?
|
| Statistics as Topic | 2 | 2015 | 104 | 0.060 |
Why?
|
| Epilepsy | 1 | 2005 | 83 | 0.050 |
Why?
|
| Warfarin | 2 | 2017 | 34 | 0.050 |
Why?
|
| Atherosclerosis | 2 | 2013 | 788 | 0.050 |
Why?
|
| Child | 3 | 2021 | 2478 | 0.050 |
Why?
|
| Socioeconomic Factors | 2 | 2017 | 436 | 0.050 |
Why?
|
| Patient Satisfaction | 2 | 2018 | 240 | 0.050 |
Why?
|
| Double-Blind Method | 2 | 2015 | 525 | 0.050 |
Why?
|
| Oxidative Stress | 1 | 2005 | 239 | 0.050 |
Why?
|
| Blindness | 1 | 2023 | 11 | 0.050 |
Why?
|
| Ethnic Groups | 1 | 2005 | 474 | 0.050 |
Why?
|
| Embolism | 1 | 2002 | 7 | 0.050 |
Why?
|
| Vision, Ocular | 1 | 2023 | 32 | 0.050 |
Why?
|
| Photic Stimulation | 1 | 2023 | 159 | 0.050 |
Why?
|
| Acute Disease | 1 | 2002 | 259 | 0.050 |
Why?
|
| Rehabilitation Centers | 1 | 2021 | 9 | 0.050 |
Why?
|
| Reproducibility of Results | 2 | 2014 | 767 | 0.050 |
Why?
|
| Visual Perception | 1 | 2023 | 116 | 0.040 |
Why?
|
| Inflammation | 2 | 2015 | 536 | 0.040 |
Why?
|
| Organ Size | 2 | 2014 | 219 | 0.040 |
Why?
|
| Health Care Surveys | 1 | 2002 | 186 | 0.040 |
Why?
|
| Cross-Sectional Studies | 2 | 2021 | 1572 | 0.040 |
Why?
|
| Body Mass Index | 2 | 2015 | 908 | 0.040 |
Why?
|
| Inpatients | 1 | 2021 | 90 | 0.040 |
Why?
|
| Methylenetetrahydrofolate Reductase (NADPH2) | 1 | 2020 | 3 | 0.040 |
Why?
|
| Viral Load | 1 | 2021 | 73 | 0.040 |
Why?
|
| Family Leave | 1 | 2020 | 2 | 0.040 |
Why?
|
| Cluster Analysis | 1 | 2021 | 126 | 0.040 |
Why?
|
| Women | 1 | 2020 | 12 | 0.040 |
Why?
|
| Career Mobility | 1 | 2020 | 15 | 0.040 |
Why?
|
| Hospital Bed Capacity | 1 | 2020 | 5 | 0.040 |
Why?
|
| Mentors | 1 | 2020 | 32 | 0.040 |
Why?
|
| Health Care Rationing | 1 | 2020 | 12 | 0.040 |
Why?
|
| Ethics, Medical | 1 | 2020 | 20 | 0.040 |
Why?
|
| Myocardial Infarction | 1 | 2004 | 483 | 0.040 |
Why?
|
| Health Resources | 1 | 2020 | 35 | 0.040 |
Why?
|
| Postal Service | 1 | 2019 | 7 | 0.040 |
Why?
|
| Polymorphism, Genetic | 1 | 2020 | 183 | 0.040 |
Why?
|
| Intensive Care Units | 1 | 2020 | 115 | 0.040 |
Why?
|
| Diabetes Mellitus | 1 | 2002 | 422 | 0.040 |
Why?
|
| Patient Care Team | 2 | 2012 | 123 | 0.040 |
Why?
|
| Republic of Korea | 1 | 2018 | 12 | 0.040 |
Why?
|
| Social Behavior | 1 | 2018 | 64 | 0.030 |
Why?
|
| Pregnancy in Diabetics | 1 | 2017 | 6 | 0.030 |
Why?
|
| Preconception Care | 1 | 2017 | 3 | 0.030 |
Why?
|
| Postnatal Care | 1 | 2017 | 5 | 0.030 |
Why?
|
| Health Services Accessibility | 1 | 2020 | 252 | 0.030 |
Why?
|
| Coronary Stenosis | 1 | 2017 | 28 | 0.030 |
Why?
|
| Cost of Illness | 1 | 2018 | 71 | 0.030 |
Why?
|
| Diabetes, Gestational | 1 | 2017 | 27 | 0.030 |
Why?
|
| Disease Management | 1 | 2018 | 128 | 0.030 |
Why?
|
| Federal Government | 1 | 2017 | 8 | 0.030 |
Why?
|
| Government Programs | 1 | 2017 | 11 | 0.030 |
Why?
|
| Pyridones | 1 | 2017 | 9 | 0.030 |
Why?
|
| International Normalized Ratio | 1 | 2017 | 9 | 0.030 |
Why?
|
| Counseling | 1 | 2017 | 98 | 0.030 |
Why?
|
| Fertility Agents | 1 | 2017 | 1 | 0.030 |
Why?
|
| Contraception | 1 | 2017 | 11 | 0.030 |
Why?
|
| Diabetic Angiopathies | 1 | 2017 | 145 | 0.030 |
Why?
|
| Hospitals, Teaching | 1 | 2017 | 30 | 0.030 |
Why?
|
| Infertility | 1 | 2017 | 14 | 0.030 |
Why?
|
| Pyrazoles | 1 | 2017 | 68 | 0.030 |
Why?
|
| Attitude of Health Personnel | 1 | 2018 | 188 | 0.030 |
Why?
|
| Animals | 2 | 2023 | 7569 | 0.030 |
Why?
|
| Health Services Research | 1 | 2017 | 81 | 0.030 |
Why?
|
| Chi-Square Distribution | 1 | 2017 | 292 | 0.030 |
Why?
|
| Stress, Psychological | 1 | 2018 | 226 | 0.030 |
Why?
|
| Survival Rate | 1 | 2018 | 894 | 0.030 |
Why?
|
| Gene Products, tat | 1 | 2015 | 1 | 0.030 |
Why?
|
| Mental Status Schedule | 1 | 2015 | 22 | 0.030 |
Why?
|
| Multivariate Analysis | 1 | 2017 | 682 | 0.030 |
Why?
|
| Inflammation Mediators | 1 | 2015 | 102 | 0.030 |
Why?
|
| Health Knowledge, Attitudes, Practice | 1 | 2018 | 360 | 0.030 |
Why?
|
| Erythroblasts | 1 | 2014 | 1 | 0.030 |
Why?
|
| Megakaryocytes | 1 | 2014 | 4 | 0.030 |
Why?
|
| Vascular Resistance | 1 | 2014 | 32 | 0.030 |
Why?
|
| Gene Regulatory Networks | 1 | 2014 | 44 | 0.030 |
Why?
|
| Work | 1 | 2014 | 6 | 0.030 |
Why?
|
| Retirement | 1 | 2014 | 13 | 0.030 |
Why?
|
| Models, Organizational | 1 | 2014 | 15 | 0.030 |
Why?
|
| Sample Size | 1 | 2014 | 39 | 0.030 |
Why?
|
| Molecular Sequence Data | 1 | 2014 | 352 | 0.030 |
Why?
|
| Neutrophils | 1 | 2014 | 110 | 0.030 |
Why?
|
| Transcription Factors | 1 | 2014 | 176 | 0.020 |
Why?
|
| Age Distribution | 1 | 2013 | 201 | 0.020 |
Why?
|
| Monocytes | 1 | 2014 | 130 | 0.020 |
Why?
|
| Heart Diseases | 1 | 2014 | 116 | 0.020 |
Why?
|
| Sensitivity and Specificity | 1 | 2014 | 576 | 0.020 |
Why?
|
| Interviews as Topic | 1 | 2013 | 272 | 0.020 |
Why?
|
| Specialties, Nursing | 1 | 2012 | 1 | 0.020 |
Why?
|
| Residence Characteristics | 1 | 2013 | 197 | 0.020 |
Why?
|
| alpha-Galactosidase | 1 | 2011 | 3 | 0.020 |
Why?
|
| Ticlopidine | 1 | 2011 | 17 | 0.020 |
Why?
|
| Protein Processing, Post-Translational | 1 | 2011 | 79 | 0.020 |
Why?
|
| RNA | 1 | 2011 | 87 | 0.020 |
Why?
|
| Up-Regulation | 1 | 2011 | 191 | 0.020 |
Why?
|
| Advisory Committees | 1 | 2010 | 34 | 0.020 |
Why?
|
| Social Class | 1 | 2011 | 93 | 0.020 |
Why?
|
| Emergencies | 1 | 2010 | 45 | 0.020 |
Why?
|
| Brain Injuries | 1 | 2010 | 91 | 0.020 |
Why?
|
| Statistics, Nonparametric | 1 | 2009 | 126 | 0.020 |
Why?
|
| Drug Administration Schedule | 1 | 2009 | 271 | 0.020 |
Why?
|
| Dose-Response Relationship, Drug | 1 | 2009 | 622 | 0.020 |
Why?
|
| Headache | 1 | 2007 | 75 | 0.020 |
Why?
|
| Reference Values | 1 | 2007 | 238 | 0.020 |
Why?
|
| Continental Population Groups | 1 | 2007 | 236 | 0.010 |
Why?
|
| Hispanic Americans | 1 | 2011 | 930 | 0.010 |
Why?
|
| Oximes | 1 | 2004 | 6 | 0.010 |
Why?
|
| Heart Failure | 1 | 2011 | 695 | 0.010 |
Why?
|
| Piperidines | 1 | 2004 | 120 | 0.010 |
Why?
|
| Survival Analysis | 1 | 2004 | 486 | 0.010 |
Why?
|
| Smoking | 1 | 2007 | 531 | 0.010 |
Why?
|
| Attitude to Health | 1 | 2004 | 163 | 0.010 |
Why?
|